PSTV logo

PSTV
Plus Therapeutics Inc

22,132
Mkt Cap
$39.46M
Volume
3.69M
52W High
$1.22
52W Low
$0.1634
PE Ratio
-0.17
PSTV Fundamentals
Price
$0.2146
Prev Close
$0.23
Open
$0.2282
50D MA
$0.2676
Beta
1.42
Avg. Volume
6.52M
EPS (Annual)
-$0.2877
P/B
7.45
Rev/Employee
$186,178.57
$27.57
Loading...
Loading...
News
all
press releases
Plus Therapeutics (PSTV) Reports Break-Even Earnings for Q4
Plus (PSTV) delivered earnings and revenue surprises of +100.00% and +2.02%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·18d ago
News Placeholder
More News
News Placeholder
Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates
Nektar (NKTR) delivered earnings and revenue surprises of +35.47% and +128.59%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·18d ago
News Placeholder
Guardian Pharmacy Services (GRDN) Surpasses Q4 Earnings and Revenue Estimates
Guardian Pharmacy (GRDN) delivered earnings and revenue surprises of +37.04% and +2.41%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·19d ago
News Placeholder
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Beats Revenue Estimates
CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of +6.01% and +38.05%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Plus Therapeutics, Inc. (NASDAQ:PSTV) Given Average Rating of "Moderate Buy" by Brokerages
Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the company...
MarketBeat·2mo ago
News Placeholder
Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV - Get Free Report) have been given an average recommendation of "Moderate Buy" by the seven brokerages that are presently covering the company...
MarketBeat·3mo ago
News Placeholder
Plus Therapeutics (NASDAQ:PSTV) Earns "Buy" Rating from D. Boral Capital
D. Boral Capital reissued a "buy" rating and issued a $5.00 price target on shares of Plus Therapeutics in a research report on Thursday...
MarketBeat·4mo ago
News Placeholder
Plus Therapeutics' (PSTV) Buy Rating Reiterated at D. Boral Capital
D. Boral Capital reaffirmed a "buy" rating and issued a $5.00 price objective on shares of Plus Therapeutics in a research report on Monday...
MarketBeat·4mo ago
News Placeholder
HC Wainwright Expects Weaker Earnings for Plus Therapeutics
Plus Therapeutics, Inc. (NASDAQ:PSTV - Free Report) - Research analysts at HC Wainwright reduced their FY2027 EPS estimates for shares of Plus Therapeutics in a report issued on Wednesday, November...
MarketBeat·4mo ago
News Placeholder
What is HC Wainwright's Estimate for PSTV Q1 Earnings?
Plus Therapeutics, Inc. (NASDAQ:PSTV - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Plus Therapeutics in a research note...
MarketBeat·4mo ago
<
1
2
...
>

Latest PSTV News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.